CEL-SCI (CVM) Competitors $0.56 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends CVM vs. IVA, ADVM, CNTX, VTYX, FTLF, RPTX, CRDF, OTLK, CGEN, and CADLShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Inventiva (IVA), Adverum Biotechnologies (ADVM), Context Therapeutics (CNTX), Ventyx Biosciences (VTYX), FitLife Brands (FTLF), Repare Therapeutics (RPTX), Cardiff Oncology (CRDF), Outlook Therapeutics (OTLK), Compugen (CGEN), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Inventiva Adverum Biotechnologies Context Therapeutics Ventyx Biosciences FitLife Brands Repare Therapeutics Cardiff Oncology Outlook Therapeutics Compugen Candel Therapeutics CEL-SCI (NYSE:CVM) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability. Is CVM or IVA more profitable? Inventiva's return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -239.31% -102.69% Inventiva N/A N/A N/A Does the media prefer CVM or IVA? In the previous week, Inventiva had 10 more articles in the media than CEL-SCI. MarketBeat recorded 10 mentions for Inventiva and 0 mentions for CEL-SCI. Inventiva's average media sentiment score of 0.64 beat CEL-SCI's score of 0.00 indicating that Inventiva is being referred to more favorably in the news media. Company Overall Sentiment CEL-SCI Neutral Inventiva Positive Which has more risk & volatility, CVM or IVA? CEL-SCI has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Do analysts rate CVM or IVA? Inventiva has a consensus target price of $14.00, indicating a potential upside of 414.71%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable valuation and earnings, CVM or IVA? CEL-SCI has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$32.19M-$0.58-0.97Inventiva$15.62M9.14-$119.51MN/AN/A Do institutionals & insiders have more ownership in CVM or IVA? 12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 16.2% of CEL-SCI shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor CVM or IVA? Inventiva received 19 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 79.17% of users gave Inventiva an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote. CompanyUnderperformOutperformCEL-SCIOutperform VotesNo VotesUnderperform Votes9100.00% InventivaOutperform Votes1979.17% Underperform Votes520.83% SummaryInventiva beats CEL-SCI on 13 of the 14 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$35.75M$2.91B$5.06B$19.82BDividend YieldN/A1.79%5.06%3.50%P/E Ratio-0.9741.06100.7142.14Price / SalesN/A217.681,206.6120.65Price / CashN/A178.0140.7521.65Price / Book2.004.096.324.66Net Income-$32.19M-$42.42M$119.47M$983.45M7 Day Performance-23.05%-10.63%-5.11%-2.12%1 Month Performance-42.25%-6.02%-3.21%-0.47%1 Year Performance-74.88%26.36%32.43%24.69% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCIN/A$0.56flatN/A-74.9%$35.74MN/A-0.9743Analyst UpgradeNews CoverageIVAInventiva3.1661 of 5 stars$2.72+2.3%N/A-33.3%$142.74M$15.62M0.00100Analyst ForecastShort Interest ↓News CoverageGap UpADVMAdverum Biotechnologies4.1022 of 5 stars$6.86-5.4%N/A-22.9%$142.69M$3.60M-1.15190Short Interest ↓News CoverageCNTXContext Therapeutics2.4434 of 5 stars$1.84-3.2%N/A+82.2%$142.50MN/A-2.027Gap DownVTYXVentyx Biosciences2.6067 of 5 stars$1.87-5.1%N/A-20.8%$139.30MN/A-0.7973News CoverageFTLFFitLife Brands4.5229 of 5 stars$30.26-8.5%N/A+52.6%$139.20M$52.70M18.8020Short Interest ↓Analyst RevisionNews CoverageHigh Trading VolumeRPTXRepare Therapeutics2.9956 of 5 stars$3.11-4.3%N/A-44.1%$132.21M$51.13M-1.56180CRDFCardiff Oncology1.3314 of 5 stars$2.58-9.2%N/A+143.4%$131.92M$490,000.00-2.7420Short Interest ↑OTLKOutlook Therapeutics1.9658 of 5 stars$5.41-1.8%N/A-38.0%$128.00MN/A-0.5120Positive NewsCGENCompugen2.758 of 5 stars$1.41-5.4%N/A+126.1%$125.82M$42.72M70.5068Earnings ReportShort Interest ↓News CoverageCADLCandel Therapeutics0.2468 of 5 stars$3.80-11.6%N/A+268.9%$121.92M$120,000.00-2.2560Short Interest ↑News Coverage Related Companies and Tools Related Companies Inventiva Competitors Adverum Biotechnologies Competitors Context Therapeutics Competitors Ventyx Biosciences Competitors FitLife Brands Competitors Repare Therapeutics Competitors Cardiff Oncology Competitors Outlook Therapeutics Competitors Compugen Competitors Candel Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CVM) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
